Wikipedia

Beckley Foundation

TheBeckley Foundationis a UK-basedthink tankand UN-accreditedNGO,dedicated to activating globaldrug policy reformand initiating scientific research into psychoactive substances. The foundation is acharitable trustwhich collaborates with leading scientific and political institutions worldwide to design and develop research and global policy initiatives. It also investigatesconsciousnessand its modulation from a multidisciplinary perspective, working in collaboration with scientists. The foundation is based atBeckley ParknearOxford,United Kingdom.It was founded in 1998, and is directed byAmanda Feilding, Countess of Wemyss.

Beckley Foundation
Formation1998
TypeECOSOCAccreditedNGO
Legal statusCharitable trust
PurposeScientific researchanddrug policy reform
Location
Director
Amanda Feilding
(Directorandfounder)
Websitebeckleyfoundation.org

Background

edit

Since its creation by Amanda Feilding in 1998, the Beckley Foundation has been at the forefront of global drug policy reform[1]and scientific research intopsychoactive substances.

The Beckley Foundation Scientific Programme initiates, designs and conducts research into the effects of psychoactive substances on the brain, in order to minimise their potential harms, learn more about consciousness and brain function, and discover and explore their therapeutic potential. Recent research includes collaborations with Dr Jordi Riba at Sant Pau Hospital onayahuasca,ProfessorDavid NuttatImperial Collegeon the effects ofpsychedelicson cerebral blood flow, Professor Valerie Curran atUniversity College Londonon the effects ofcannabison the brain with a view to possible therapeutic applications and with ProfessorRoland R. GriffithsatJohns Hopkins Universitystudying the effects ofpsilocybinin combating addiction.

The Beckley Foundation Policy Programme is dedicated to improving national and global drug policies, through research that increases understanding of thehealth,socialandfiscalimplications of drug policy, and the development of newevidence-basedand rational approaches. It brings together country representatives, science and policy experts at international seminars in order to discuss alternative drug policy, and commissions and disseminates reports[2]to open up and facilitate debate among policy-makers and the public.

Policy

edit

The Beckley Foundation Drug Policy Programme

edit

The Beckley Foundation Drug Policy Programme was created to promote rational discussion on delicate global arrangement issues.[3]It intended to provide drug strategy advice to academics, substance misuse specialists, strategy developers, and the general public. Senior officials, top researchers, and practitioners evaluated the most recent data on the success of drug policies.

International Therapeutic Psilocybin Rescheduling Initiative (ITPRI)

edit

In 2022, the Beckley Foundation joined in the launch of the International Therapeutic Psilocybin Rescheduling Initiative, a global coalition working to promote and secure a rescheduling of psilocybin under the 1971 Convention on Psychotropic Substances. The ITPRI is seeking a worldwide policy change in order to facilitate research into the therapeutic potential of the substance. Partners of the coalition include the Multidisciplinary Association for Psychedelic Studies (MAPS), Mind Medicine Australia, Drug Science and Open Foundation.[4]

Roadmaps to Regulation: New Psychoactive Substances 2016

edit

To coincide with the introduction of the UK's Psychoactive Substances Act 2016[5]on 26 May 2016, Amanda Feilding released the report, "Roadmaps to Regulation: New Psychoactive Substances".[6]The document surveys the complex and unique world of NPS production and distribution and suggests a harm reductive model for the legal regulation of this vast array of substances. The NPS report is part of wider family of forthcoming reports, "Roadmaps to Regulation: Cannabis, Psychedelics, MDMA and NPS".[7]

Beckley Foundation Guatemala 2012–13

edit

On 3 July 2012 Beckley Foundation Guatemala was launched after the organisation had been asked to convene an international Board of Experts to write reports which would:

  1. analyse the impact of the current drug prohibitionist policies;
  2. propose a sophisticated range of alternative policy solutions forGuatemala.

The alternative drug policy solutions were presented to PresidentOtto Pérez Molinaby Amanda Feilding in January 2013 in this 'Paths for Reform' report. The suggestions include a proposal to investigate legalising the illicit opium poppy crop in order to produce pain-relieving medications for the Guatemalan people,[8]an initiative that has been mentioned by President Pérez Molina during Davos 2013 and other official appearances[9]

Public Letter 2011

edit

In 2011 anopen letterfrom the Foundation was published inThe TimesandThe Guardiancalling for a new approach to drug policy. The letter opened by emphatically stating that the war on drugs has failed and calling for a new approach. Signatories of the letter now include the current Presidents ofColombia(Juan Manuel Santos) andGuatemala(Otto Pérez Molina), and former Presidents of theUnited States(Jimmy Carter),Mexico,ColombiaandSwitzerland,as well asNobel Prizewinners and numerous other world figures.[10]

Science

edit

The Beckley Foundation is one of the few organisations in the world initiating, supporting, and directing scientific research investigating the effects of currently-controlled psychoactive substances.[11]This ground-breaking research explores how substances such as cannabis, psychedelics, and MDMA act upon the human brain, using the latest developments in neuroscience and brain imaging technology. The purpose of the research is to increase our scientific understanding of consciousness itself, and to explore new avenues for the treatment of illnesses and the betterment of humankind. Over the last 18 years, the Programme has produced dozens of scientific articles published in influential peer-reviewed journals,[12]andAmanda Feildinghas spearheaded numerous collaborations. Collaborating partners include leading institutions such asImperial College London,Sant Pau Hospital,University College London,King's College London,and Johns Hopkins University, and topics have covered:

  • changes in brain structure, function, and blood supply in response to cannabis,[13][14]LSD,[15]psilocybin,[16]ayahuasca/DMT,[17]and MDMA;[18]
  • LSD, psilocybin, and MDMA-assisted psychotherapy for conditions such as depression,[19]anxiety, addiction, and post-traumatic stress disorder (PTSD);
  • cannabis and cannabinoids in the treatment of brain cancer;
  • LSD in the treatment of cluster headaches; and
  • cerebral circulation, cranial compliance, and their relationship to age-related cognitive decline.

Latest findings from the Beckley Foundation scientific programme

edit

Ayahuasca and Neurogenesis 2016

edit

A preliminary study conducted within the framework of the Beckley-Sant Pau Research Programme and in collaboration with the Spanish National Research Council found that harmine and tetrahydroharmine, the alkaloids present in highest amounts inayahuasca,have potent neurogenic properties (the ability to create new brain cells). The addition of harmine and tetrahydroharmine to cultures containing neural stem cells dramatically increased their differentiation and maturation into neurons.[20]

Psilocybin for Depression 2016

edit

Based on the Beckley/Imperial Research Programme's psilocybin study brain imaging results, in 2012, the Medical Research Council awarded funding to the programme for a clinical study investigating psilocybin in the treatment of depression. Results from the study, published in the Lancet Psychiatry Journal, showed that two doses of psilocybin lifted depression in all 12 volunteers for three weeks, and kept five of them depression free for three months.[21]

LSD Revealed 2016

edit

On 13 April 2016, the Beckley/Imperial Research Programme released the world's first images[22]of the human brain on LSD,[23]collected as part of the first ever brain imaging study to examine the effects of LSD on the human brain. Programme co-directorsAmanda FeildingandDavid Nutt,together with lead-investigatorRobin Carhart-Harris,held a press conference at the Royal Society on 11 April 2016 to herald the publication of the paper.[24]

Beckley Canopy Therapeutics

edit

News reports in 2018-2019 indicated that the Foundation had been retained by the Canadian cannabis producerCanopy Growth Corporationto conduct research as to the benefits of various strains of its products, particularly in treating pain, anxiety and drug addiction. One goal is to reduce dependence on opioids in treating cancer-related pain. The two formed Beckley Canopy Therapeutics in Oxford, to raise funds from investors for cannabinoid research and drug development.

Canopy Growth has been planning to export its products to the UK.[25]The long-term intent of the partnership is to confirm the value of cannabis in specific conditions and to convince insurers to pay for medical cannabis when used accordingly. Mark Ware, Canopy's chief medical officer, said in an interview that Feilding's "ability to take a scientific look at what would otherwise be considered as controversial therapeutics makes her a very good partner".[26]

Feilding's son, Cosmo Feilding Mellen, is the managing director of the partnership.[27][28]

Ongoing projects and collaborations

edit
  • The Beckley/Maastricht Microdosing Research Programme at Maastricht University in the Netherlands, carrying out research into the effects of LSD microdosing on humans, with a particular focus on mood, cognitive functions, and pain management. The first study, exploring the dose-response relationship in LSD-induced physiological and psychological effects, saw twenty-four healthy volunteers each receive single doses of 5, 10 and 20 micrograms of LSD, or a placebo.

Past projects and collaborations

edit
  • The Beckley Foundation/Imperial College LondonPsychedelic Research Programme, investigating the effects of psilocybin and other psychedelic drugs on cerebral blood flow, and linking this with cognitive effects (for example, improved episodic memory recall and increased vividness of subjective experience under the influence of psilocybin).
  • The Beckley Foundation Ethnobotanical Research Programme, investigating the effects and potential benefits of Ayahuasca and DMT, including a study involving ketanserin on evaluating the effects of glutamate release by DMT, a study investigating the association between brain plasticity and Ayahuasca, and a long-term study investigating the effect of Ayahuasca on personal development and health.
  • A Beckley Foundation/Johns Hopkins Universitycollaboration investigating the potential use of psychedelic drugs to treat addiction. A pilot study using psilocybin to treat nicotine addiction produced promising results, leading to a multi-site clinical trial in the USA, funded by NIH, in which the Foundation is not involved.
  • A Beckley Foundation/King's College Londoncollaboration with Dr Paul Morrison at the Institute of Psychiatry investigating the differing effects of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), two of the main cannabinoids found in cannabis that determine its subjective and cognitive effects. Cannabidiol is showing promise in inhibiting the psychosis-like effects of THC, and indicating great therapeutic potential.
  • A Beckley Foundation/University College Londoncollaboration with Professor Valerie Curran investigating medicinal uses of cannabis.
  • A Beckley/Imperial Psychedelic Research Programme collaborative study onpsychedelic microdosing.[29][30]

Recent Scientific Journal Publications

edit
  • Lebedev, Alexander V.; Lövdén, Martin; Rosenthal, Gidon; Feilding, Amanda; Nutt, David J.; Carhart-Harris, Robin L. (2015)."Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin".Human Brain Mapping.36(8): 3137–3153.doi:10.1002/hbm.22833.PMC6869189.PMID26010878.
  • Carhart-Harris, R. L.; Kaelen, M.; Whalley, M. G.; Bolstridge, M.; Feilding, A.; Nutt, D. J. (2014). "LSD enhances suggestibility in healthy volunteers".Psychopharmacology.232(4): 785–794.doi:10.1007/s00213-014-3714-z.PMID25242255.S2CID15592659.
  • Carhart-Harris, Robin L.; Leech, Robert; Hellyer, Peter J.; Shanahan, Murray; Feilding, Amanda; Tagliazucchi, Enzo; Chialvo, Dante R.; Nutt, David (2014)."The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs".Frontiers in Human Neuroscience.8:20.doi:10.3389/fnhum.2014.00020.PMC3909994.PMID24550805.
  • Carhart-Harris, R. L.; Wall, M. B.; Erritzoe, D.; Kaelen, M.; Ferguson, B.; De Meer, I.; Tanner, M.; Bloomfield, M.; Williams, T. M.; Bolstridge, M.; Stewart, L.; Morgan, C. J.; Newbould, R. D.; Feilding, A.; Curran, H. V.; Nutt, D. J. (2013)."The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories".The International Journal of Neuropsychopharmacology.17(4): 527–540.doi:10.1017/S1461145713001405.PMID24345398.
  • Muthukumaraswamy, S. D.; Carhart-Harris, R. L.;Moran, R. J.;Brookes, M. J.; Williams, T. M.; Errtizoe, D.; Sessa, B.; Papadopoulos, A.; Bolstridge, M.; Singh, K. D.; Feilding, A.; Friston, K. J.; Nutt, D. J. (2013)."Broadband Cortical Desynchronization Underlies the Human Psychedelic State".Journal of Neuroscience.33(38): 15171–15183.doi:10.1523/JNEUROSCI.2063-13.2013.PMC6618409.PMID24048847.
  • Carhart-Harris, R. L.; Leech, R.; Williams, T. M.; Erritzoe, D.; Abbasi, N.; Bargiotas, T.; Hobden, P.; Sharp, D. J.; Evans, J.; Feilding, A.; Wise, R. G.; Nutt, D. J. (2018)."Implications for psychedelic-assisted psychotherapy: Functional magnetic resonance imaging study with psilocybin".British Journal of Psychiatry.200(3): 238–244.doi:10.1192/bjp.bp.111.103309.PMID22282432.

Beckley Foundation Press Publications

edit

The Beckley Foundation Press was created to allow the publication of Drug Policy and Scientific material that was not being picked up by mainstream publishing houses due to the controversial nature of the material.

Authors: Albert Hofmann. Translated by Jonathan Ott and Edited by Amanda Feilding - Publisher: The Beckley Foundation Press and Oxford University Press (2013).ISBN978-0-19-963941-0,248 pages

Authors: Robin Room, Benedikt Fischer, Wayne Hall, Simon Lenton and Peter Reuter, Convened by Amanda Feilding - Publisher: The Beckley Foundation Press and Oxford University Press (2010).ISBN978-0-19-958148-1

Authors: Annelie Hintzen M.D. and Torsten Passie M.D., M.A. Paperback: App 200 pages - Publisher: The Beckley Foundation Press and Oxford University Press (June 2010) ISBN978-0-19-958982-1

Edited by Amanda Feilding - Publisher: Beckley Foundation Press (2010) ISBN978-0-9548054-9-4

Authors: Yuri Moskalenko, Amanda Feilding and Peter Halvorson - Publisher: Beckley Foundation Press (2010) ISBN978-1-907072-01-7

Major Seminars

edit

See also

edit

References

edit
  1. ^Feilding, Amanda (23 June 2016)."The war on drugs is failing – decriminalisation is the only way forward | Amanda Feilding".The Guardian.
  2. ^"Policy Reports and Briefing Papers".14 April 2016.
  3. ^"The Beckley Foundation Drug Policy Programme".The Beckley Foundation Drug Policy Programme.Retrieved4 October2022.
  4. ^Jaeger, Kyle (11 January 2022)."Global Coalition Launches Push To Reschedule Psilocybin Under International Rules".Marijuana Moment.Retrieved13 January2022.
  5. ^"Psychoactive Substances Act 2016".19 November 2018.
  6. ^"Drugs should be moderated, not banned – the new ban will push more users into danger".Independent.co.uk.4 June 2016.
  7. ^"Roadmaps to Regulation: Cannabis, Psychedelics, MDMA, and NPS".15 May 2015.
  8. ^"Paths for Reform Report: Proposed Options for Alternative Drug Policies in Guatemala".Archived fromthe originalon 18 April 2013.Retrieved27 March2013.
  9. ^"Pérez Molina valora legalizar cultivos de amapola | elPeriódico de Guatemala".Archived fromthe originalon 29 April 2014.Retrieved27 March2013.
  10. ^"The global war on drugs has failed - It is time for a new approach".
  11. ^Tom, Peterkin (27 November 2011)."Countess courts rich and famous to end drug war".The Scotsman.
  12. ^"Science Publications".29 March 2016.
  13. ^"Cannabis/Cannabinoids".11 April 2017.
  14. ^"LSD For Major Depression".19 March 2023.
  15. ^"LSD Home".12 April 2017.
  16. ^"Psilocybin".6 April 2017.
  17. ^"Hallucinogenic Amazonian Medicine Stimulates Generation of New Brain Cells".30 June 2016.
  18. ^Kamboj, Sunjeev K.; Kilford, Emma J.; Minchin, Stephanie; Moss, Abigail; Lawn, Will; Das, Ravi K.; Falconer, Caroline J.; Gilbert, Paul; Curran, H Valerie; Freeman, Tom P. (2015)."Recreational 3,4-methylenedioxy-N-methylamphetamine (MDMA) or 'ecstasy' and self-focused compassion: Preliminary steps in the development of a therapeutic psychopharmacology of contemplative practices"(PDF).Journal of Psychopharmacology.29(9): 961–970.doi:10.1177/0269881115587143.PMID25990558.S2CID18605313.
  19. ^Feilding, Amanda (17 May 2016)."We saw magic mushrooms lift long-term depression. It's time for a change of perception | Amanda Feilding".The Guardian.
  20. ^"Recent advances in the study of Ayahuasca - Jordi Riba".YouTube.30 June 2016.Archivedfrom the original on 22 December 2021.
  21. ^Carhart-Harris, Robin L.; Bolstridge, Mark; Rucker, James; Day, Camilla M J.; Erritzoe, David; Kaelen, Mendel; Bloomfield, Michael; Rickard, James A.; Forbes, Ben; Feilding, Amanda; Taylor, David; Pilling, Steve; Curran, Valerie H.; Nutt, David J. (2016)."Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study".The Lancet Psychiatry.3(7): 619–627.doi:10.1016/S2215-0366(16)30065-7.PMID27210031.
  22. ^"The brain on LSD revealed: First scans show how the drug affects the brain | Imperial News | Imperial College London".11 April 2016.
  23. ^"This is your brain on LSD, literally".12 April 2016.
  24. ^Cormier, Zoe (2016). "Brain scans reveal how LSD affects consciousness".Nature.doi:10.1038/nature.2016.19727.S2CID146946079.
  25. ^"First Cannabis Clinical Trials All Set in UK".Cannabis Industry Journal. 19 December 2018.Retrieved2 April2019.Beckley Canopy Therapeutics, based in Oxford, England has raised £7.4 million for the purposes of cannabinoid research and drug development. The new company is a unique partnership established between Canopy Growth Corporation and the Beckley Foundation, a research institute which examines the utilization of psychotropic drugs for the treatment of physical and mental conditions. Studies focusing on the use of cannabinoids for the treatment of opioid addiction and cancer pain will be conducted in Europe, the UK and the US... This is exactly the kind of high-placed, societally influential effort in other words, that might finally break the medical taboo at the most important remaining logjam– at the point of prescription and approval for patients.
  26. ^"The Countess of Cannabis".Bloomberg News.1 April 2019.Retrieved2 April2019.
  27. ^"Beckley Canopy Therapeutics raises £7.4m for cannabis R&D".PharmaForum. 4 December 2018.Retrieved2 April2019.As a new business partnership investing in UK medicine and research, we would like the government to ensure that access to medicinal cannabis is as simple and straightforward as possible for patients.
  28. ^"The Countess of Cannabis".Bloomberg News.1 April 2019.Retrieved2 April2019.
  29. ^"We Are Recruiting for a New Psychedelic Microdosing Study!".The Beckley Foundation.3 September 2018.Retrieved11 March2019.
  30. ^"LSD Microdosing Research".The Beckley Foundation.25 January 2017.Retrieved11 March2019.
edit
Retrieved from "https://en.wikipedia.org/w/index.php?title=Beckley_Foundation&oldid=1245081874"